Water-soluble undenatured type II collagen ameliorates collagen-induced arthritis in mice

Journal of Medicinal Food

Volumn 16, Issue 11, 2013, Pages 1039-1045

  Yoshinari, Orie ^a,b   Shiojima, Yoshiaki ^a   Moriyama, Hiroyoshi ^a,b   Shinozaki, Junichi ^b   Nakane, Takahisa ^b   Masuda, Kazuo ^b   Bagchi, Manashi ^a  

^a Ryusendo Co Ltd   (Japan)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

CD4 + CD25 + Treg; Collagen induced arthritis; Foxp3; Oral tolerance; Rheumatoid arthritis; TGF ; Undenatured type II collagen

Indexed keywords

ANTIRHEUMATIC AGENT; CD4 ANTIGEN; COLLAGEN TYPE 2; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; NEXT II; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; UNDENATURED COLLAGEN TYPE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, CD4; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CHICKENS; COLLAGEN TYPE II; DENDRITIC CELLS; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-6; MALE; MICE; MICE, INBRED DBA; SOLUBILITY; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA1; WATER;

EID: 84887970040     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2013.2911     Document Type: Article

References (40)

1. Feldmann M: Pathogenesis of arthritis: recent research progress. Nat Immunol 2001;2:771-773.
2. Wooley PH, Luthra HS, Stuart JM, David CS: Type II collageninduced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J ExpMed 1981;154:688-700.
3. Romagnani S: Human Th17 cells. Arthritis Res Ther 2008;10: 206-213.
4. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin JJ, Garrone P, Garcia E, Saeland S, Blanchard D, Gaillard C, Das Mahapatra B, Rouvier E, Golstein P, Banchereau J, Lebecque S: T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996;183:2593-2603.
5. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T: IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345-1352.
6. Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H, Maslinski W: High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000;164:2832-2838.
7. Baecher-Allan C, Wolf E, Hafler DA: Functional analysis of highly defined, FACS-isolated populations of human regulatory CD4 + CD25 + T cells. Clin Immunol 2005;115:10-18.
8. Kohm AP, Carpentier PA, Anger HA, Miller SD: Cutting edge: CD4 + CD25 + regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol 2002;169:4712-4716.
9. Morgan ME, Flierman R, van Duivenvoorde LM, Witteveen HJ, van Ewijk W, van Laar JM, de Vries RR, Toes RE: Effective treatment of collagen-induced arthritis by adoptive transfer of CD25 + regulatory T cells. Arthritis Rheum 2005;52:2212-2221.
10. Frey O, Petrow PK, Gajda M, Siegmund K, Huehn J, Scheffold A, Hamann A, Radbruch A, Bräuer R: The role of regulatory T cells in antigen-induced arthritis: aggravation of arthritis after depletion and amelioration after transfer of CD4 + CD25 + T cells. Arthritis Res Ther 2005;7:R291-R301.
11. Morgan ME, Sutmuller RP, Witteveen HJ, van Duivenvoorde LM, Zanelli E, Melief CJ, Snijders A, Offringa R, de Vries RR, Toes RE: CD25 + cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum 2003;48:1452-1460.
12. Zheng SG, Wang J, Wang P, Gray JD, Horwitz DA: IL-2 is essential for TGF-beta to convert naive CD4 + CD25-cells to CD25 + Foxp3 + regulatory T cells and for expansion of these cells. J Immunol 2007;178:2018-2027.
13. Davidson TS, DiPaolo RJ, Andersson J, Shevach EM: Cutting Edge: IL-2 is essential for TGF-beta-mediated induction of Foxp3 + T regulatory cells. J Immunol 2007;178:4022-4026.
14. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6:1133-1141.
15. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B: TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006;24:179-189.
16. Pasare C, Medzhitov R: Toll pathway-dependent blockade of CD4 + CD25 + T cell-mediated suppression by dendritic cells. Science 2003;299:1033-1036.
17. Ivanov II, Zhou L, Littman DR: Transcriptional regulation of Th17 cell differentiation. Semin Immunol 2007;19:409-417.
18. Weiner HL: Oral tolerance, an active immunologic process mediated by multiple mechanisms. J Clin Invest 2000;106:935-937.
19. Nagler-Anderson C, Bober LA, Robinson ME, Siskind GW, Thorbecke GJ: Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci USA 1986;83:7443-7446.
20. Thorbecke GJ, Schwarcz R, Leu J, Huang C, Simmons WJ: Modulation by cytokines of induction of oral tolerance to type II collagen. Arthritis Rheum 1999;42:110-118.
21. Park KS, Park MJ, Cho ML, Kwok SK, Ju JH, Ko HJ, Park SH, Kim HY: Type II collagen oral tolerance; mechanism and role in collagen-induced arthritis and rheumatoid arthritis. Mod Rheumatol 2009;19:581-589.
22. Sagawa K, Nagatani K, Komagata Y, Yamamoto K: Angiotensin receptor blockers suppress antigen-specific T cell responses and ameliorate collagen-induced arthritis in mice. Arthritis Rheum 2005;52:1920-1928.
23. Bancroft JD, Steven A: Theory and Practice of Histological Techniques, 3rd edition. Churchill Livingstone, New York, 1990.
24. Kobayashi S, Terato K, Harada Y, Moriya H, Taniguchi M: Suppression of type II collagen-induced arthritis by monoclonal antibodies. Arthritis Rheum 1991;34:48-54.
25. Ohnishi Y, Tsutsumi A, Sakamaki T, Sumida T: T cell epitopes of type II collagen in HLA-DRB1*0101 or DRB1*0405-positive Japanese patients with rheumatoid arthritis. Int J Mol Med 2003; 11:331-335.
26. Hua J, Sakamoto K, Nagaoka I: Inhibitory actions of glucosamine, a therapeutic agent for osteoarthritis, on the functions of neutrophils. J Leukoc Biol 2002;71:632-640.
27. Gouze JN, Gouze E, Popp MP, Bush ML, Dacanay EA, Kay JD, Levings PP, Patel KR, Saran JP, Watson RS, Ghivizzani SC: Exogenous glucosamine globally protects chondrocytes from the arthritogenic effects of IL-1beta. Arthritis Res Ther 2006;8: R173-R186.
28. Ivanovska N, Dimitrova P: Bone resorption and remodeling in murine collagenase-induced osteoarthritis after administration of glucosamine. Arthritis Res Ther 2011;13:R44-R56.
29. Yudoh K, Matsuno H, Nakazawa F, Yonezawa T, Kimura T: Reduced expression of the regulatory CD4 + T cell subset is related to Th1/Th2 balance and disease severity in rheumatoid arthritis. Arthritis Rheum 2000;43:617-627.
30. Min SY, Hwang SY, Park, KS, Lee JS, Lee KE, Kim KW, Jung YO, Koh HJ, Do JH, Kim H, Kim HY: Induction of IL-10-producing CD4 + CD25 + T cells in animal model of collageninduced arthritis by oral administration of type II collagen. Arthritis Res Ther 2004;6:R213-R219.
31. Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4 + CD25 + regulatory T cells. Nat Immunol 2003;4:330-336.
32. Wang TY, Li J, Li CY, Jin Y, Lü XW, Wang XH, Zhou Q: Leflunomide induces immunosuppression in collagen-induced arthritis rats by upregulating CD4 + CD25 + regulatory T cells. Can J Physiol Pharmacol 2010;88:45-53.
33. Marie JC, Letterio JJ, Gavin M, Rudensky AY: TGF-beta1 maintains suppressor function and Foxp3 expression in CD4 + CD25 + regulatory T cells. J Exp Med 2005;201:1061-1067.
34. Zheng SG, Wang J, Horwitz DA: Cutting edge: Foxp3+CD4+ CD25+ regulatory T cells induced by IL-2 and TGF-beta are resistant to Th17 conversion by IL-6. J Immunol 2008;180:7112-7116.
35. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY: A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005;6:1142-1151.
36. Wan S, Xia C, Morel L: IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4 + CD25 + T cell regulatory functions. J Immunol 2007;178:271-279.
37. Dominitzki S, Fantini MC, Neufert C, Nikolaev A, Galle PR, Scheller J, Monteleone G, Rose-John S, Neurath MF, Becker C: Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4 + CD25 T cells. J Immunol 2007;179:2041-2045.
38. Fehérvári Z, Sakaguchi S: Control of Foxp3 + CD25 + CD4 + regulatory cell activation and function by dendritic cells. Int Immunol 2004;16:1769-1780.
39. Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S: Foxp3 + natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci USA 2008;105:10113-10118.
40. Zheng X, Suzuki M, Ichim TE, Zhang X, Sun H, Zhu F, Shunnar A, Garcia B, Inman RD, Min W: Treatment of autoimmune arthritis using RNA interference-modulated dendritic cells. J Immunol 2010;184:6457-6464.